How would you treat isolated axillary recurrence of a previously node negative ER/PR+, HER2- breast cancer after prior neoadjuvant chemotherapy, lumpectomy/adjuvant RT, and adjuvant AI?

The problem of isolated local or regional recurrence has been a vexing one for years. There have been multiple attempts to complete a randomized trial with sufficient numbers to draw conclusions and none have succeeded. I was Principal Investigator for one such Intergroup trial in the 1980's closed ...

proviso. Since the relapse was greater than a year after start of A.I. one could consider reintroduction of an A.I. rather than Fulvestrant.

Fosladex plus ibrance